$VOR News

Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Vor Bio Announces Conditional China National Medicinal Products Administration Approval Of Telitacicept For The Treatment Of Adult Patients With IgAN

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $31 Price Target

We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $18

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?

HC Wainwright & Co. Maintains Buy on Vor Biopharma, Lowers Price Target to $31

Vor Biopharma: It's A Game Of Wait And See

Vor Biopharma (VOR) Upgraded to Buy: Here's Why

Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)